182400 — NKGen Biotech Korea Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro Cap

Annual cashflow statement for NKGen Biotech Korea Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	R2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS/A	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	—	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-51,079	-55,607	-117,108	-36,942	-7,342
Depreciation
Amortisation
Non-Cash Items	5,565	7,119	126,521	33,218	5,633
Unusual Items
Other Non-Cash Items
Changes in Working Capital	2,906	921	-26,990	2,438	-1,692
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-34,155	-38,063	-9,076	-1,258	-3,202
Capital Expenditures	-1,379	-926	-672	-5,011	-902
Purchase of Fixed Assets
Other Investing Cash Flow Items	13,260	-147	-9,463	7,635	2,090
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Change in Net Intangibles
Other Investing Cash Flow
Cash from Investing Activities	11,881	-1,074	-10,135	2,624	1,188
Financing Cash Flow Items	14,390	36,000	8,500	2,320	—
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	19,364	32,884	15,049	1,131	-90.9
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-3,714	-5,844	-5,251	2,423	-2,095